Martindale Joshua J, Metzger Joseph M
Department of Integrative Biology and Physiology, University of Minnesota Medical School, Minneapolis, MN, USA.
Department of Integrative Biology and Physiology, University of Minnesota Medical School, Minneapolis, MN, USA.
J Mol Cell Cardiol. 2014 Feb;67:26-37. doi: 10.1016/j.yjmcc.2013.12.008. Epub 2013 Dec 19.
Myocardial ischemia/reperfusion (I/R) injury is a major clinical problem leading to cardiac dysfunction and myocyte death. It is widely held that I/R causes damage to membrane phospholipids, and is a significant mechanism of cardiac I/R injury. Molecular dissection of sarcolemmal damage in I/R, however, has been difficult to address experimentally. We studied here cardiac I/R injury under conditions targeting gain- or loss-of sarcolemma integrity. To implement gain-in-sarcolemma integrity during I/R, synthetic copolymer-based sarcolemmal stabilizers (CSS), including Poloxamer 188 (P188), were used as a tool to directly stabilize the sarcolemma. Consistent with the hypothesis of sarcolemmal stabilization, cellular markers of necrosis and apoptosis evident in untreated myocytes were fully blocked in sarcolemma stabilized myocytes. Unexpectedly, sarcolemmal stabilization of adult cardiac myocytes did not affect the status of myocyte-generated oxidants or lipid peroxidation in two independent assays. We also investigated the loss of sarcolemmal integrity using two independent genetic mouse models, dystrophin-deficient mdx or dysferlin knockout (Dysf KO) mice. Both models of sarcolemmal loss-of-function were severely affected by I/R injury ex vivo, and this was lessened by CSS. In vivo studies also showed that infarct size was significantly reduced in CSS-treated hearts. Mechanistically, these findings support a model whereby I/R-mediated increased myocyte oxidative stress is uncoupled from myocyte injury. Because the sarcolemma stabilizers used here do not transit across the myocyte membrane this is evidence that intracellular targets of oxidants are not sufficiently altered to affect cell death when sarcolemma integrity is preserved by synthetic stabilizers. These findings, in turn, suggest that sarcolemma destabilization, and consequent Ca(2+) mishandling, as a focal initiating mechanism underlying myocardial I/R injury.
心肌缺血/再灌注(I/R)损伤是导致心脏功能障碍和心肌细胞死亡的主要临床问题。人们普遍认为,I/R会损害膜磷脂,这是心脏I/R损伤的一个重要机制。然而,对I/R过程中肌膜损伤进行分子剖析在实验上一直难以解决。我们在此研究了在针对肌膜完整性增加或丧失的条件下的心脏I/R损伤。为了在I/R期间实现肌膜完整性增加,基于合成共聚物的肌膜稳定剂(CSS),包括泊洛沙姆188(P188),被用作直接稳定肌膜的工具。与肌膜稳定的假设一致,未处理的心肌细胞中明显的坏死和凋亡细胞标志物在肌膜稳定的心肌细胞中被完全阻断。出乎意料的是,在两项独立试验中,成年心肌细胞的肌膜稳定并未影响心肌细胞产生的氧化剂或脂质过氧化的状态。我们还使用两种独立的基因小鼠模型,即肌营养不良蛋白缺陷的mdx或dysferlin基因敲除(Dysf KO)小鼠,研究了肌膜完整性的丧失。两种肌膜功能丧失模型在体外均受到I/R损伤的严重影响,而CSS可减轻这种影响。体内研究还表明,CSS处理的心脏梗死面积显著减小。从机制上讲,这些发现支持了一个模型,即I/R介导的心肌细胞氧化应激增加与心肌细胞损伤脱钩。由于这里使用的肌膜稳定剂不会穿过心肌细胞膜,这证明当通过合成稳定剂保持肌膜完整性时,氧化剂的细胞内靶点没有发生足够的改变来影响细胞死亡。这些发现反过来表明,肌膜不稳定以及随之而来的Ca(2+)处理不当,是心肌I/R损伤的一个局部起始机制。